EL7.AI
StocksMediumUpdated•Originally published 4 August 2026•Updated 4 August 2026•
1 min read

High Tide Forecasts Record Q3 Results Beating Analyst Estimates

Man in a suit centered between maps of Canada and Germany, above a digital dashboard showing Q3 earnings data.

Key Facts

1High Tide expects record revenue between C$195M and C$200M for the third fiscal quarter of 2026.
2The company's Adjusted EBITDA guidance of C$15.2M to C$16.5M exceeds the analyst consensus of C$14.0M.
3The company announced a record distribution of over 10 tonnes of medical cannabis flower in the German market.

In a move reflecting accelerated growth within the legal cannabis sector, High Tide has issued optimistic guidance for its third fiscal quarter ending July 31, 2026. The company expects to report record revenue between C$195M and C$200M, driven by robust retail performance. According to reports, Adjusted EBITDA is projected to reach between C$15.2M and C$16.5M, significantly exceeding the analyst consensus of C$14.0M.

This positive outlook is partly attributed to international success, with the company announcing a record distribution of over 10 tonnes of medical cannabis flower in the German market via Remexian Pharma GmbH. Per market data, this volume represents a 60% year-over-year increase in Germany. These results come as the company continues to expand its footprint, currently holding approximately 12% of the Canadian bricks-and-mortar market share.

High Tide is scheduled to release its full financial and operational results for the third fiscal quarter after market close on September 14, 2026. Regarding the broader economic context, US CB Consumer Confidence data released on July 28, 2026, stood at 90.8, missing the 92.4 forecast, which underscores the importance of monitoring consumer spending power in the company's key markets moving forward.